Skeletal Ryanodine Receptors Are Involved in Impaired Myogenic Differentiation in Duchenne Muscular Dystrophy...

Area of Science:

• Muscle physiology and cellular biology
• Genetic and neuromuscular disorders
• Calcium signaling in muscle

Background:

• Duchenne muscular dystrophy (DMD) is marked by muscle wasting, inadequate regeneration, and impaired myogenesis.
• Intracellular calcium (Ca2+) mishandling is a key factor in DMD pathogenesis.
• The type 1 ryanodine receptor (RYR1) mediates Ca2+ release crucial for skeletal muscle differentiation.

Purpose of the Study:

• To investigate if altered RYR1-mediated Ca2+ release contributes to impaired myogenic differentiation in DMD patients.
• To explore the role of RYR1 dysfunction in the cellular mechanisms underlying DMD.
• To assess the therapeutic potential of modulating RYR1 activity in DMD.

Main Methods:

• Comparison of primary myoblasts from DMD patients and healthy controls.
• Silencing RYR1 expression in control myoblasts using siRNA.
• Measurement of intracellular Ca2+ concentrations and RYR1-mediated Ca2+ release.
• Assessment of myogenic differentiation and RYR1-calstabin interaction.

Main Results:

• DMD myoblasts exhibited delayed differentiation compared to controls.
• RYR1 silencing in healthy myoblasts mimicked the delayed differentiation observed in DMD.
• Increased resting intracellular Ca2+ was found in DMD myotubes, without altered RYR1-mediated release.
• RYR1 stabilization with S107 normalized Ca2+ levels, improved differentiation, and enhanced calstabin1 binding in DMD myotubes.
• Intracellular Ca2+ levels correlated with endomysial fibrosis, a marker of poor motor outcome.

Conclusions:

• RYR1-mediated Ca2+ leakage contributes significantly to impaired myogenic differentiation in human DMD.
• RYR1 stabilization represents a promising adjunctive therapeutic strategy for Duchenne muscular dystrophy.
• Modulating RYR1 activity may offer a novel approach to address both cellular dysfunction and motor impairment in DMD.